TNGXNGMHealthcare·Biotechnology#73 in industry

Tango Therapeutics, Inc.

Reports in 14d· 2026-05-11

+122.2% · 90d

$26.33

+0.58 (+2.25%)

After-Hours $26.34(+0.01)

News

No News Yet

Press releases and SEC filings for TNGX will appear here as they are published.

Check back later for updates

Key Data

Market Cap$3.80B

Open$26.32

Prev Close$25.75

Day Range$25.79 – $27.10

52W Range$1.03 – $28.41

Volume2,599,951

P/E (TTM)—

EPS$-0.87

Dividend Yield—

Beta1.31

Profit Margin-162.85%

Revenue Growth-100.00%

Price Target$23.90(-9.2%)

Next Earnings2026-05-11(14d)

Analyst Ratings

Strong Buy12 analysts

Buy 11Hold 1Sell 0

About

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Healthcare · Biotechnology

137 employees

www.tangotx.com